Icon

VITRAKVI (nda210861)- (EQ 25MG BASE,EQ 100MG BASE)

LAROTRECTINIB SULFATE BAYER HLTHCARE
EQ 25MG BASE,EQ 100MG BASE
No No
2036-Aug-15 2023-Nov-26
None None
None No
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:  have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,  are metastatic or where surgical resection is likely to result in severe morbidity, and  have no satisfactory alternative treatments or that have progressed following treatment.
0 0 0
Total Other Developers 5
Drugs with Suitability No
EQ 25MG BASE ** ** - - -
EQ 100MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.